Filtered By:
Vaccination: Veterinary Vaccinations

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 437 results found since Jan 2013.

An investigation and assessment of the muscle damage and inflammation at injection site of aluminum-adjuvanted vaccines in guinea pigs
In this study, muscle damage caused by several Al containing vaccines were examined in guinea pigs. Mild and moderate inflammation were observed following Al containing split influenza virus vaccine, formalin-inactivated diphtheria-pertussis-tetanus and Salk polio vaccine. While massive inflammation and muscle damage were observed in Al-containing human papillomavirus vaccine-inoculated animals. However, the severities of damage were not associated with their Al contents. Masson's trichrome staining and immunostaining revealed that injured muscle at the inoculated site recovered within one month of vaccination, whereas inf...
Source: Journal of Toxicological Sciences - November 3, 2022 Category: Toxicology Authors: Eita Sasaki Keiko Furuhata Takuo Mizukami Isao Hamaguchi Source Type: research

New trends in immunocastration and its potential to improve animal welfare: a mini review
AbstractCastration is frequently used to reduce aggressive behavior and improve the meat quality of animals. Traditionally, surgical and mechanical castration are used to sterilize the animals, but these approaches are associated with a high level of pain, stress, long recovery periods, and post-operative infections. Immunocastration is a new animal-friendly, painless alternative castration technique that is used to prevent undesired sexual behavior, reduce aggressive behavior, prevent unwanted pregnancy, control wildlife populations and wandering species, enhance growth performance, improve meat quality, and treat various...
Source: Tropical Animal Health and Production - November 2, 2022 Category: Veterinary Research Source Type: research

Uganda Reports Worrisome Increase in Ebola Cases in Capital
KAMPALA, Uganda — Ugandan officials have reported 11 more cases of Ebola in the capital since Friday, a worrisome increase in infections just over a month after an outbreak was declared in a remote part of the East African country. Nine more people in the Kampala metropolitan area tested positive for Ebola on Sunday, in addition to two others on Friday, Health Minister Jane Ruth Aceng said Monday. A top World Health Organization official in Africa said last week that Uganda’s Ebola outbreak was “rapidly evolving,” describing a challenging situation for health workers. Ugandan health authorities have...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Rodney Muhumuza/AP Tags: Uncategorized Disease healthscienceclimate wire Source Type: news

Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-na ïve adults
CONCLUSIONS: Vaccination of hookworm-naïve adults with recombinant Na-APR-1(M74) was well-tolerated, safe, and induced significant IgG responses against the vaccine antigen Na-APR-1(M74). Given these favorable results, clinical trials of this product were initiated in hookworm-endemic areas of Gabon and Brazil.PMID:36114129 | DOI:10.1016/j.vaccine.2022.09.017
Source: Vaccine - September 16, 2022 Category: Allergy & Immunology Authors: David J Diemert Maria Zumer Doreen Campbell Shannon Grahek Guangzhao Li Jin Peng Maria Elena Bottazzi Peter Hotez Jeffrey Bethony Source Type: research

U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 18, 2022 Edition-----The main issue, probably of the year, is the increasing tension across the Taiwan Strait with all sorts of worries about how conflict can be avoided and prosperity maintained at a reasonable level as tensions continue. And hopefully ease.The impact of climate change in Europe is really becoming obvious and worrying. I am not sure just how a realistic response is possible in any reasonable time.In OZ the PM has come back after a week off to have the Chinese Ambassador tell us we are a vassal and to just shut up and behave. Astonishing and serious stuff IMVHO.-----Major Issues.-----https://www.smh...
Source: Australian Health Information Technology - August 18, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

What to Know About the Monkeypox Drug TPOXX —And Why It ’ s So Hard to Get
Monkeypox, which federal officials declared a public health emergency on August 4, is not as contagious as the other ongoing public health emergency in the U.S.: COVID-19. Monkeypox primarily spreads through contact with infected skin lesions. Theoretically, containing monkeypox should therefore be more feasible, as long as testing, vaccines, and treatments are accessible. But in reality, the rollouts of all three approaches have faced major challenges. Getting the antiviral drug tecovirimat, also known as TPOXX, is particularly difficult. Here’s what to know about the antiviral drug treatment TPOXX. What is TPOXX? T...
Source: TIME: Health - August 9, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate monkeypox Source Type: news

The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 04, 2022 Edition-----The war seems to grind on sadly and Pres. Biden is having a second round with COVID as unprecedented weather happens all over the US. It all feels rather like ‘the end of days’!In the UK we see an increasing chance of a third female PM being elected as the country seems to be struggling. We do need to remember however the UK remains a significant power with nuclear weapons and home-grown nuclear submarines!In OZ we have had last week working out how to progress the First Nations ‘Voice’ as we wrap up the 1st session of Parliament for the new Government. Comments welcome on how you think ...
Source: Australian Health Information Technology - August 4, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news